PHARMOSA BIOPHARM INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.4 TWD | -0.13% |
|
-0.52% | -13.18% |
| Sales 2022 | - | Sales 2023 | 314.5 10.21K | Capitalization | 10.31B 335B |
|---|---|---|---|---|---|
| Net income 2022 | -267M -8.67B | Net income 2023 | 8M 260M | EV / Sales 2022 | - |
| Net cash position 2022 | 651M 21.14B | Net cash position 2023 | 830M 26.93B | EV / Sales 2023 | 30,156,637 x |
| P/E ratio 2022 |
-23.5
x | P/E ratio 2023 |
1,257
x | Employees | 40 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.54% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.13% | ||
| 1 week | -0.52% | ||
| 1 month | +3.95% | ||
| 3 months | -34.42% | ||
| 6 months | -13.28% | ||
| Current year | -13.18% |
1 week
75.30
79.00
1 month
66.5082.70
Current year
64.10125.50
1 year
64.10162.00
3 years
31.00162.00
5 years
31.00162.00
10 years
31.00162.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pei Kan
CEO | Chief Executive Officer | - | 18-03-31 |
Shu Ping Yang
DFI | Director of Finance/CFO | - | 15-05-31 |
Ko Chieh Chen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Jen Wu
BRD | Director/Board Member | - | 22-01-09 |
Ko Jui Shih
BRD | Director/Board Member | - | 21-10-24 |
Wen Chang Chang
BRD | Director/Board Member | - | 22-01-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 76.4 | -0.13% | 145,242 |
| 24-05-30 | 76.5 | -0.26% | 273,316 |
| 24-05-29 | 76.7 | +0.52% | 143,159 |
| 24-05-28 | 76.3 | +0.93% | 167,910 |
| 24-05-27 | 75.6 | -1.56% | 250,068 |
End-of-day quote Taipei Exchange, May 30, 2024
More quotes
Pharmosa Biopharm Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The main products include L606, for the treatment of Category I pulmonary arterial hypertension (PAH); L606, for the treatment of Category III pulmonary hypertension caused by interstitial lung disease (PH-ILD); L606, for the treatment of chronic thromboembolic Category IV pulmonary hypertension (CTEPH); L608, for the treatment of Category I pulmonary arterial hypertension (PAH).
| 1st Jan change | Capi. | |
|---|---|---|
| -13.18% | 305M | |
| +43.36% | 58.06B | |
| -5.31% | 40.53B | |
| +37.52% | 38.99B | |
| +14.75% | 26.7B | |
| -12.56% | 26.56B | |
| -22.45% | 18.98B | |
| +0.04% | 12.17B | |
| +25.12% | 12B | |
| +26.04% | 11.92B |
- Stock Market
- Equities
- 6875 Stock
